All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
S14 Ep51: Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD
OncLive® On Air
14 minutes
4 days ago
S14 Ep51: Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD
In today’s episode, we had the pleasure of speaking with Justin Taylor, MD, an associate professor in the Division of Hematology at the University of Miami Miller School of Medicine, about the growing role of artificial intelligence in cancer information–seeking and what this means for clinicians caring for patients with hematologic malignancies. Dr Taylor’s recent work explores how patients are increasingly turning to AI tools to better understand their diagnoses and treatments, and why oncologists must be aware of the accuracy, limitations, and clinical implications of these technologies.
OncLive® On Air
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
